Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 941-948

  Mouly, Stéphane J ^a,c   Paine, Mary F ^a   Watkins, Paul B ^a,b,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HUMAN SERUM ALBUMIN; MIDAZOLAM; OROSOMUCOID; PLASMA PROTEIN; SAQUINAVIR; ZOSUQUIDAR;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CATALYSIS; CELL LEVEL; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FIRST PASS EFFECT; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROXYLATION; INTESTINE; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTI-HIV AGENTS; BLOOD PROTEINS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; GABA MODULATORS; HUMANS; MIDAZOLAM; P-GLYCOPROTEIN; SAQUINAVIR;

EID: 1342323340     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.056390     Document Type: Article

References (34)

1. Alsenz J, Steffen H, and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res (NY) 15:423-428.
2. Artursson P (1990) Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476-482.
3. Buss N, Snell P, Bock J, Hsu A, and Jorga K (2001) Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 52:255-264.
4. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143-144.
5. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, and Wrighton SA (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854-862.
6. Eagling VA, Wiltshire H, Whitcombe IW, and Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
7. 3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 289:1134-1142.
8. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
9. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, and Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344-349.
10. Hochman JH, Chiba M, Nishime J, Yamazaki M, and Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:310-318.
11. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated α-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 29:299-303.
12. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, and Leonard JM (1998) Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464.
13. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, and Schinkel AH (2002) Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors and transport can be enhanced by other drugs. AIDS 16:2295-2391.
14. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, and Schinkel AH (2001) P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
15. Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, Flora KP, and Mitsuya H (1994) Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother 38:1107-1111.
16. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, and Saag MS (2000) Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 44:2672-2678.
17. Kim AE, Dintaman JM, Waddell DS, and Silverman JA (1998a) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
18. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998b) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
19. Kodjo A, Crivat M, Bondon H, Trout H, Dumitrescu L, Vittecoq, D, Dohin E, Goerhs JM, and Bergmann JF (1997) Digestive absorption of saquinavir in AIDS patients with severe diarrhea or wasting syndrome. Gastroenterology 112:A1016.
20. Krishna G, Chen K, Lin C, and Nomeir AA (2001) Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 222:77-89.
21. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359.
22. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
23. Lown KS, Balley DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Investig 99:2545-2553.
24. Meunier V, Bourrie M, Berger Y, and Fabre G (1995) The human intestinal epithelial cell line Caco-2: pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194.
25. Mouly S, Aymard G, Diquet B, Caulin C, and Bergmann JF (2000) Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. J Acquir Immune Defic Syndr 24:344-351.
26. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
27. Paine MF, Leung LY, Lim HR, Liao K, Oganesian A, Zhang MY, Thummel KE, and Watkins PB (2002) Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther 301:174-186.
28. Perry CM and Noble S (1998) Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
29. 3. Mol Pharmacol 51:741-754.
30. 3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 29:1446-1453.
31. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
32. Thummel KE, Kunze KL, and Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
33. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, and Blaschke TF (2000) The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats and in cultured cells. Drug Metab Dispos 28:1058-1062.
34. Williams PEO, Muirhead GJ, Madigan MJ, Mitchell AM, and Shaw T (1992) Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 34:155P-156P.